Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very low doses of rituximab for off-label treatment – Pilot Trial
2016-002478-11Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in autoimmune haemolytic anaemia (AIHA) and antiphospholipid syndrome (APS) (3 arms), sponsored by Medical University of Vienna. Primary endpoint: CD19/20+ cell counts. Started Jul 2016; status: terminated.
02
Drugs
rituximab
03
Conditions
autoimmune haemolytic anaemia (AIHA)antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2016-002478-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002478-11.